HRD Cancer

2 clinical trials · Condition

Record	Firm	Date
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway (NCT06614751)	Danatlas Pharmaceuticals Co., Ltd	2024-11-01
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)	National Cancer Institute (NCI)	2021-09-20

Every clearance here is in the API, with alerts when new ones post.